RecruitingPhase 2NCT05999383

Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration


Sponsor

University of California, San Francisco

Enrollment

48 participants

Start Date

Jul 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.


Eligibility

Min Age: 21 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cannabis, a drug called Nicotine, and others for people with cannabis, cannabis smoking, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCannabis

Participants will vape marijuana in varying doses from the PAX device

DRUGNicotine

Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device

DEVICEPax Loose Leaf Vaporizer

In all arms, participants will be using the PAX Loose Leave Vaporizer.

OTHERPlacebo Marijuana

Participants will vape placebo marijuana from the PAX device


Locations(1)

Zuckerberg San Francisco General Hospital

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05999383


Related Trials